Angel Quevedo
Research Subjects
Research Interests
Angel Quevedo has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Ailiyomar Perez
Menydial
1 shared publication - Alfonso Silva Contreras
Contigo S.A. Dialicon Quito, Ecuador
1 shared publication - Cristhian Mejía
Hospital San Vicente de Paul
1 shared publication - Daniel Arias
Fresenius Medical Care, Ecuador
1 shared publication - David Garrido
Hospital de clínicas Dr. Manuel Quintela, Montevideo, Uruguay
1 shared publication - Evelyn Moreira
Unidad de Hemodiálisis, Fresenius Medical Care, Ecuador
1 shared publication
Latest Publications
- Open Access
- 3 March 2025
- Published by Sociedad Ecuatoriana de Nefrologia, Dialisis y Trasplantes in Revista de la Sociedad Ecuatoriana de Nefrología, Diálisis y Trasplante
- Vol. 13 (2) , 91-97
Prevalence of multiple myeloma in patients on hemodialysis programs
Introduction: Multiple myeloma (MM) is a hematological malignancy that often causes kidney failure, affecting more than 50% of MM patients. Kidney damage in MM is primarily due to cast nephropathy, light chain deposition disease, and amyloidosis. However, there are no data on MM patients undergoing hemodialysis in Ecuador. This study aims to report the prevalence of MM in the country's hemodialysis units. Methods: This observational, descriptive, cross-sectional, multicenter study evaluated the prevalence of MM in hemodialysis patients in Ecuador. A survey was distributed to 23 nephrologists, collecting data on the total number of hemodialysis patients and those diagnosed with MM. Prevalence was calculated using the formula: Prevalence = (MM patients / Total hemodialysis patients) × 1000. Data were analyzed using nonparametric methods in R v4.3.2, with 99% confidence intervals. Results: were diagnosed with MM, yielding a prevalence of 1.1% (95% CI: 0.7% to 1.6%), or 11.3 cases per 1000 hemodialysis patients. The number of MM cases varied by city, with the highest number reported in Portoviejo (10 cases) and none in Riobamba. Conclusion: The prevalence of MM in Ecuador is consistent with international reports, with similar findings in the United States (1.0%), Nigeria (0.81%), and other Latin American countries. These findings highlight the need for a national registry to better understand the needs of MM patients on hemodialysis.
- 3 March 2025
- Published by Sociedad Ecuatoriana de Nefrologia, Dialisis y Trasplantes in Revista de la Sociedad Ecuatoriana de Nefrología, Diálisis y Trasplante
- Vol. 13 (2) , 91-97
Open AccessPrevalence of multiple myeloma in patients on hemodialysis programs
Introduction: Multiple myeloma (MM) is a hematological malignancy that often causes kidney failure, affecting more than 50% of MM patients. Kidney damage in MM is primarily due to cast nephropathy, light chain deposition disease, and amyloidosis. However, there are no data on MM patients undergoing hemodialysis in Ecuador. This study aims to report the prevalence of MM in the country's hemodialysis units. Methods: This observational, descriptive, cross-sectional, multicenter study evaluated the prevalence of MM in hemodialysis patients in Ecuador. A survey was distributed to 23 nephrologists, collecting data on the total number of hemodialysis patients and those diagnosed with MM. Prevalence was calculated using the formula: Prevalence = (MM patients / Total hemodialysis patients) × 1000. Data were analyzed using nonparametric methods in R v4.3.2, with 99% confidence intervals. Results: were diagnosed with MM, yielding a prevalence of 1.1% (95% CI: 0.7% to 1.6%), or 11.3 cases per 1000 hemodialysis patients. The number of MM cases varied by city, with the highest number reported in Portoviejo (10 cases) and none in Riobamba. Conclusion: The prevalence of MM in Ecuador is consistent with international reports, with similar findings in the United States (1.0%), Nigeria (0.81%), and other Latin American countries. These findings highlight the need for a national registry to better understand the needs of MM patients on hemodialysis.